PRNewsWire
19 Nov 2026, 16:53 UTC · 1h ago
Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman
Impact · against what's priced in
CADL faces significant downward pressure and legal risk following a BLA submission delay and a subsequent securities fraud investigation. For NVDA, the updated investigation by Hagens Berman represents a marginal legal headwind that does not fundamentally shift the AI growth narrative currently baked into the price.
- NVDA−0.10
Not in the price yet
- In context
The update to an ongoing investigation by Hagens Berman introduces potential legal noise, but does not impact the core AI revenue CAGR or hardware architecture milestones the market is monitoring.





